Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled maintenance study of subcutaneous CT-P13 in moderately to severely active ulcerative colitis
MOH_2020-04-07_008843Phase 3Not yet recruiting
- Sponsor
- Celltrion
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab in autoimmune colitis (2 arms), sponsored by Celltrion. Primary endpoint: Clinical remission at week 54. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2020-04-07_008843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-07_008843.